

Immunology House Keeping and Admin 04 | 15 Nov 2021

Staffing

- a) Sherly did a did well in training. Competent in running Immunocap and Evolis. Introduced to CBAs. Lynsey will complete asparaginase training in Dec when she is with us again for a week.

Changes to existing tests or requests for changes

- a) Received the quote for ENA characterisation reagents late Friday. Will order wells today, as well as the Immunotrol controls as potential replacement for Autoantibody IQC.

New Tests or equipment

- a)

Quality Assurance

- a) *5.5.1.4 M The laboratory is requested to confirm if measurement uncertainty was calculated for Phadia (new method). MU was calculated for existing methods on new Phadia 250 instruments. Steve has emailed a screen shot of this doc to Jodie.*
- b) *5.1.8 M1 The laboratory is requested to detail how the effectiveness of the continuing education program will be periodically reviewed. **Periodic review will be assessed at the annual performance review. Does there need to be an assessment?** This is for Anat Path, not Immuno.*
- c) *4.1 C The laboratory is requested to confirm how it intends to monitor that the supervisory requirements are on track to being met through the year. Head of department response.*

Due 26 November 2021

- d) Received Asparaginase German EQAP this morning. Will start testing samples today.

Stock / Inventory

IT issues / Network Issues

- a)

Projects / Trials

- a) CBA dilutions on patients with >200 results. Serial dilution and normal patient samples included. CBA kits expire late Feb 2022.
- b) Plate reader validation for Asparaginase underway. CBAs started.

Attendee list

Steve Schischka, Lynsey Peach, Jocelyn Shackles, Mayumi Knight

Sign off will be reviewed during each Performance appraisal cycle – please sign off in MTS